var data={"title":"Clinical manifestations and diagnosis of chronic paracoccidioidomycosis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Clinical manifestations and diagnosis of chronic paracoccidioidomycosis</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/contributors\" class=\"contributor contributor_credentials\">Marcio Nucci, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/contributors\" class=\"contributor contributor_credentials\">Arnaldo L Colombo, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/contributors\" class=\"contributor contributor_credentials\">Carol A Kauffman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/contributors\" class=\"contributor contributor_credentials\">Jennifer Mitty, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Sep 15, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Paracoccidioidomycosis is a systemic endemic mycotic disease caused by the thermally dimorphic fungi of the genus <em>Paracoccidioides</em>. Two species are recognized to cause paracoccidioidomycosis: <em>Paracoccidioides brasiliensis</em> and <em>Paracoccidioides lutzii</em>. The fungus has a geographic distribution limited to Central and South America, where paracoccidioidomycosis is the most frequent systemic endemic mycosis.</p><p>The clinical manifestations and diagnosis of chronic paracoccidioidomycosis will be reviewed here. The clinical manifestations and diagnosis of <span class=\"nowrap\">acute/subacute</span> paracoccidioidomycosis as well as the mycology, epidemiology, and treatment of paracoccidioidomycosis are discussed separately. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-acute-subacute-paracoccidioidomycosis\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of acute/subacute paracoccidioidomycosis&quot;</a> and <a href=\"topic.htm?path=mycology-and-epidemiology-of-paracoccidioidomycosis\" class=\"medical medical_review\">&quot;Mycology and epidemiology of paracoccidioidomycosis&quot;</a> and <a href=\"topic.htm?path=treatment-of-paracoccidioidomycosis\" class=\"medical medical_review\">&quot;Treatment of paracoccidioidomycosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Following inhalation, <em>Paracoccidioides </em>spp typically cause asymptomatic pulmonary infection. If the infection is not contained by the host, the disease may evolve into one of two patterns: the chronic form, which represents reactivation of the primary infection and is most common, or the <span class=\"nowrap\">acute/subacute</span> form [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/1\" class=\"abstract_t\">1</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-acute-subacute-paracoccidioidomycosis\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of acute/subacute paracoccidioidomycosis&quot;</a>.)</p><p>Over 90 percent of cases of paracoccidioidomycosis are the chronic form, which may present months or years following the primary infection [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/2\" class=\"abstract_t\">2</a>]. It most commonly affects men who work in agriculture, and are between 30 and 60 years of age [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/3\" class=\"abstract_t\">3</a>]. (See <a href=\"topic.htm?path=mycology-and-epidemiology-of-paracoccidioidomycosis#H3\" class=\"medical medical_review\">&quot;Mycology and epidemiology of paracoccidioidomycosis&quot;, section on 'Epidemiology'</a>.) </p><p><em>Paracoccidioides </em>spp can disseminate to any part of the body by the hematogenous or lymphatic routes. Thus, as with other systemic endemic fungal infections, any organ can be affected. Signs and symptoms usually progress slowly, and may be related to a single organ or to several organs. (See <a href=\"topic.htm?path=mycology-and-epidemiology-of-paracoccidioidomycosis#H8\" class=\"medical medical_review\">&quot;Mycology and epidemiology of paracoccidioidomycosis&quot;, section on 'Pathogenesis'</a>.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Signs and symptoms</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The chronic form of the disease usually presents as pulmonary infiltrates and upper respiratory mucosal lesions [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/4\" class=\"abstract_t\">4</a>]. Unifocal disease occurs in only 25 percent of cases and is most commonly described in the lungs [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/2\" class=\"abstract_t\">2</a>]. Disease can be severe, and in one study that evaluated 6732 hospitalizations due to paracoccidioidomycosis, the overall in-hospital mortality was 5 percent [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/5\" class=\"abstract_t\">5</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h3\">Lungs</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The lungs are frequently involved in chronic paracoccidioidomycosis, either alone or with other organs. In a review of 352 patients with paracoccidioidomycosis, 77 percent had lung involvement [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/2\" class=\"abstract_t\">2</a>]. Dry cough and dyspnea are the most frequent presenting symptoms, but sputum production and hemoptysis may occur in some patients [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/6\" class=\"abstract_t\">6</a>]. However, it is common for patients to present with extensive lung involvement (including fibrosis) with few or no symptoms of pulmonary disease [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/7,8\" class=\"abstract_t\">7,8</a>]. This is important because there is an increased risk of progressive pulmonary fibrosis among patients with more extensive radiologic findings at the initial presentation [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/8\" class=\"abstract_t\">8</a>]. (See <a href=\"#H8\" class=\"local\">'Sequelae'</a> below and <a href=\"#H7\" class=\"local\">'Radiographic findings'</a> below.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h3\">Mucosa</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Mucosal involvement occurs in over 50 percent of cases. The mouth (oropharynx, lips, tongue, gingiva, palate) is most frequently affected, followed by the larynx [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/9-12\" class=\"abstract_t\">9-12</a>]. The typical lesion is a painful ulcer with ragged borders and small spots of hemorrhage (<a href=\"image.htm?imageKey=ID%2F69875\" class=\"graphic graphic_picture graphicRef69875 \">picture 1</a> and <a href=\"image.htm?imageKey=ID%2F62412\" class=\"graphic graphic_picture graphicRef62412 \">picture 2</a>). Patients complain of soreness, sialorrhea, hoarseness, odynophagia, <span class=\"nowrap\">and/or</span> dysphagia.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h3\">Other sites</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Other sites that can be involved in patients with chronic paracoccidioidomycosis include the skin [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/13\" class=\"abstract_t\">13</a>], lymph nodes [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/14\" class=\"abstract_t\">14</a>], adrenal glands [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/15\" class=\"abstract_t\">15</a>], and central nervous system (<a href=\"image.htm?imageKey=ID%2F62412\" class=\"graphic graphic_picture graphicRef62412 \">picture 2</a>) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/16\" class=\"abstract_t\">16</a>]. Adrenal lesions are very common in patients with disseminated disease; this involvement is manifested by asymptomatic limited adrenal reserve in 15 to 40 percent and, less commonly, by Addison's disease in approximately 3 percent [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/15,17\" class=\"abstract_t\">15,17</a>]. Less frequently involved organs include bones [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/18,19\" class=\"abstract_t\">18,19</a>], joints [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/18\" class=\"abstract_t\">18</a>], genital organs [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/20\" class=\"abstract_t\">20</a>] and eyes [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/21,22\" class=\"abstract_t\">21,22</a>].</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Radiographic findings</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lung imaging (chest radiograph or computed tomography [CT]) typically reveals mixed interstitial and alveolar infiltrates, which are usually perihilar, bilateral, and symmetrical with predominantly lower lung field involvement (<a href=\"image.htm?imageKey=ID%2F63969\" class=\"graphic graphic_diagnosticimage graphicRef63969 \">image 1</a>) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/2,6,8,23\" class=\"abstract_t\">2,6,8,23</a>]. The most frequent images on chest CT are ground-glass attenuations, consolidations, nodules, masses, cavities, and septal or interlobular thickening; the reversed halo sign may be present [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/24\" class=\"abstract_t\">24</a>]. Long-standing pulmonary involvement may lead to serious sequelae such as fibrosis, bullae, and emphysema (<a href=\"image.htm?imageKey=ID%2F74974\" class=\"graphic graphic_diagnosticimage graphicRef74974 \">image 2</a>) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/4,8\" class=\"abstract_t\">4,8</a>].</p><p>Central nervous system radiographic findings typically include ring enhancing lesions located in the cerebrum, thalamus, cerebellum, brainstem, <span class=\"nowrap\">and/or</span> spinal cord (<a href=\"image.htm?imageKey=ID%2F63969\" class=\"graphic graphic_diagnosticimage graphicRef63969 \">image 1</a>) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/16\" class=\"abstract_t\">16</a>].</p><p>Joint involvement is characterized by effusion, periarticular bony erosions, <span class=\"nowrap\">and/or</span> narrowing of the joint space, whereas the typical radiographic finding of bone involvement is bone lysis with or without a rim of sclerosis [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/18\" class=\"abstract_t\">18</a>].</p><p>Other radiographic findings depend upon which organs are affected. (See <a href=\"#H3\" class=\"local\">'Signs and symptoms'</a> above.)</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Sequelae</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>An important aspect of chronic paracoccidioidomycosis is the development of sequelae, mostly represented by chronic respiratory failure that results from fibrosis (<a href=\"image.htm?imageKey=ID%2F74974\" class=\"graphic graphic_diagnosticimage graphicRef74974 \">image 2</a>), and limited adrenal reserve or Addison's disease [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/4,8\" class=\"abstract_t\">4,8</a>]. Other sequelae include emphysema, formation of bullae, and pulmonary arterial hypertension [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/4,8\" class=\"abstract_t\">4,8</a>]. Microstomia and stenosis of the glottis <span class=\"nowrap\">and/or</span> trachea with associated dysphonia can also occur (<a href=\"image.htm?imageKey=ID%2F57011\" class=\"graphic graphic_picture graphicRef57011 \">picture 3</a>) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/2\" class=\"abstract_t\">2</a>]. (See <a href=\"#H4\" class=\"local\">'Lungs'</a> above and <a href=\"#H6\" class=\"local\">'Other sites'</a> above.)</p><p>Early diagnosis is important to help prevent progression to fibrosis. As an example, in a retrospective study of 47 patients with chronic paracoccidioidomycosis who were treated with <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a> and then followed for a median of 5.6 years, fibrosis correlated with the severity of the infiltrates at the time of diagnosis. Fibrosis was detected during the study in 83 percent of those with very severe infiltrates at diagnosis compared with 13 percent of patients with mild infiltrates [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/8\" class=\"abstract_t\">8</a>]. </p><p>However, lung scarring can occur even in the setting of adequate antifungal therapy. In a study that evaluated 50 patients with inactive disease (&ge;6 months of treatment, negative mycology, resolution of skin and mucous lesions, low antibody titers), radiologic abnormalities were present on high resolution chest CT scans in 98 percent of cases [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/25\" class=\"abstract_t\">25</a>]. Findings included architectural distortion (90 percent), reticulate and septal thickening (88 percent), and centrilobular and paraseptal emphysema (84 percent). Pulmonary function and aerobic capacity were impaired in the majority of patients. </p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients with chronic paracoccidioidomycosis with lung involvement, there is a broad differential diagnosis, which includes infectious causes such as tuberculosis, fungal infections (especially histoplasmosis), and noninfectious causes such as carcinoma, sarcoidosis, and idiopathic pulmonary fibrosis [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/4,26\" class=\"abstract_t\">4,26</a>]. Upper respiratory tract involvement may be suggestive of carcinoma. Mucosal and skin findings may be similar to those of leishmaniasis.</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of paracoccidioidomycosis is based upon the microscopic visualization of fungal elements suggestive of <em>Paracoccidioides </em>spp <span class=\"nowrap\">and/or</span> by culturing this fungus from clinical specimens. Serologic testing can be useful both for diagnosis and for monitoring the response to therapy.</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Microscopy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The yeast form of <em>Paracoccidioides </em>spp can be visualized in sputum, abscess fluid, lymph node aspirates, scrapings of skin lesions, <span class=\"nowrap\">and/or</span> biopsy samples of affected organs [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/3\" class=\"abstract_t\">3</a>]. Routine methods for wet mount preparation include potassium hydroxide (KOH) and calcofluor. Direct microscopy using KOH yields a diagnosis in over 90 percent of cases [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/3\" class=\"abstract_t\">3</a>]. A positive direct exam in the proper host is highly suggestive of the diagnosis, even if culture is negative. (See <a href=\"topic.htm?path=mycology-and-epidemiology-of-paracoccidioidomycosis#H2\" class=\"medical medical_review\">&quot;Mycology and epidemiology of paracoccidioidomycosis&quot;, section on 'Mycology'</a>.)</p><p>When demonstrated in clinical samples, <em>Paracoccidioides </em>spp are characterized as large (4 to 40 microns) round or oval &quot;mother&quot; yeast cell surrounded by multiple, attached, narrow-necked budding daughter yeast cells (resembling a &quot;pilot's wheel&quot;) or mother yeast cell possessing only two attached daughter buds (resembling a &quot;Mickey mouse head&quot;) (<a href=\"image.htm?imageKey=ID%2F74383\" class=\"graphic graphic_picture graphicRef74383 \">picture 4</a>). If the typical multiple budding cells are not found, differentiation from other fungi, such as <em>Blastomyces dermatitidis</em>, can be difficult.</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Culture</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Paracoccidioides </em>spp can be cultured from sputum, biopsy samples, <span class=\"nowrap\">and/or</span> abscess fluid using Sabouraud dextrose agar or yeast extract agar containing <a href=\"topic.htm?path=chloramphenicol-drug-information\" class=\"drug drug_general\">chloramphenicol</a> and cycloheximide incubated at room temperature. The mold form of <em>Paracoccidioides </em>spp usually takes as long as 20 to 30 days to grow [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/2\" class=\"abstract_t\">2</a>]. Some authors have suggested that cultures for <em>Paracoccidioides</em> are positive in up to 80 percent of samples [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/3\" class=\"abstract_t\">3</a>]. However, in our experience, cultures are frequently negative for <em>Paracoccidioides</em> because most specimens are obtained from sites that are colonized by bacteria, which inhibit fungal growth in culture. Consequently, the final diagnosis relies on the identification of typical yeasts cells in direct exam or tissue.</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Pathology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Methenamine silver stain or periodic acid Schiff stain is used to identify fungal elements in tissue samples. The presence of the characteristic large round yeast cells with multiple narrow-necked budding yeasts establishes the diagnosis (<a href=\"image.htm?imageKey=ID%2F74383\" class=\"graphic graphic_picture graphicRef74383 \">picture 4</a>). (See <a href=\"#H11\" class=\"local\">'Microscopy'</a> above.)</p><p>Histopathologic findings include a cellular infiltrate comprised of polymorphonuclear leukocytes, monocytes, macrophages, and multinucleated giant cells, which surround the yeast cells [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/2,6\" class=\"abstract_t\">2,6</a>]. Granulomas surrounding the yeast cells are typical in patients with chronic paracoccidioidomycosis [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/6\" class=\"abstract_t\">6</a>] but may also occur in patients with acute paracoccidioidomycosis.</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Serologic tests</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong><em>P. brasiliensis</em></strong>&mdash; Detection of specific antibodies is used for the initial evaluation of patients suspected to be infected by <em>P. brasiliensis</em>. Serologic tests can also be used to monitor the response to therapy; a good clinical response is often associated with a reduction in the titer of serum antibodies. (See <a href=\"topic.htm?path=treatment-of-paracoccidioidomycosis#H22\" class=\"medical medical_review\">&quot;Treatment of paracoccidioidomycosis&quot;, section on 'Serologic testing'</a>.)</p><p/><p class=\"bulletIndent1\">Various serologic tests are available, including quantitative immunodiffusion, complement fixation, enzyme-linked immunosorbent assay (ELISA), and counterimmunoelectrophoresis [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/27\" class=\"abstract_t\">27</a>]. However, the utility of some of these serologic tests, such as complement fixation and ELISA, is limited by antigenic cross-reactivity between <em>P. brasiliensis</em> and other fungi, especially <em>Histoplasma capsulatum</em> [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/3,27\" class=\"abstract_t\">3,27</a>]. (See <a href=\"topic.htm?path=diagnosis-and-treatment-of-pulmonary-histoplasmosis\" class=\"medical medical_review\">&quot;Diagnosis and treatment of pulmonary histoplasmosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\">Quantitative immunodiffusion testing is the most widely available assay in endemic regions. When testing for <em>P. brasiliensis</em> infection, any positive result should be considered suggestive of disease [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/1\" class=\"abstract_t\">1</a>]. Immunodiffusion testing represents the most reliable method for serologic diagnosis due to its high sensitivity and specificity, and because it is simple to perform [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/3\" class=\"abstract_t\">3</a>]. As an example, in a study that used a seven-day exoantigen in the immunodiffusion assay, the sensitivity was 97 percent and the specificity was 100 percent [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/28\" class=\"abstract_t\">28</a>]. Another study, which evaluated the performance of a double immunodiffusion assay in 401 cases, reported the sensitivity and specificity as 90 percent and 100 percent, respectively [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/29\" class=\"abstract_t\">29</a>]. However, unpublished experience with a larger number of samples suggests lower sensitivity (70 to 90 percent) and specificity (&gt;90 percent). In addition, serologic testing has a lower sensitivity in immunocompromised patients, such as those with HIV infection, compared with immunocompetent individuals. (See <a href=\"#H20\" class=\"local\">'Immunocompromised hosts'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong><em>P. lutzii</em></strong> &mdash; Patients infected with <em>P. lutzii </em>may be negative for the immunodiffusion test that detects antibodies against the gp43 antigen [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/30\" class=\"abstract_t\">30</a>]. However, a test for <em>P. lutzii</em> infection using a cell-free antigen preparation has been developed. In a study evaluating sera from 17 patients who had a clinical diagnosis of paracoccidioidomycosis, but a negative serologic test using a traditional immunodiffusion assay, all patients were reactive for <em>P. Lutzii</em> by immunodiffusion using cell free antigen enzyme-linked immunosorbent assay, and Western blot [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/31\" class=\"abstract_t\">31</a>]. </p><p/><p class=\"headingAnchor\" id=\"H3302332640\"><span class=\"h2\">Skin testing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Skin testing for the paracoccidioidin antigen is not useful for diagnosis due to its low sensitivity. Furthermore, although the test may be positive in patients with active disease, it may also be positive in healthy individuals previously exposed to the fungus.</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Experimental methods</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Other diagnostic modalities are being developed, but are not yet commercially available. </p><p>Tests that detect antigen have been developed. These tests detect specific glycoprotein antigens (gp43 and gp70) in serum, cerebrospinal fluid, and bronchoalveolar lavage fluid using immunoenzymatic assays, and appear to have higher sensitivity and specificity compared with traditional antibody detection methods [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/27,32,33\" class=\"abstract_t\">27,32,33</a>]. In addition, antigen detection may be particularly useful in immunocompromised patients as serologic testing may be falsely negative [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/3\" class=\"abstract_t\">3</a>]. (See <a href=\"#H14\" class=\"local\">'Serologic tests'</a> above.)</p><p>A latex test that detects both antibodies and the gp43 antigen of <em>P. brasiliensis</em> in sera, cerebrospinal fluid, and bronchoalveolar lavage has also been developed. The sensitivity and specificity for detecting antibodies was 98 and 94 percent, and for detecting antigen was 97 and 89 percent, respectively [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/34\" class=\"abstract_t\">34</a>]. As with the other antigen tests, this assay is not available for use in clinical settings.</p><p>Polymerase chain reaction (PCR)-based DNA amplification methods have high sensitivity and specificity but are not widely available [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/35,36\" class=\"abstract_t\">35,36</a>]. PCR can differentiate between <em>P. brasiliensis </em>and <em>P. lutzii</em> by sequencing the isolates, or using matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/37\" class=\"abstract_t\">37</a>].</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h1\">EVALUATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of paracoccidioidomycosis is sought in patients who present with suggestive epidemiological and clinical findings. A typical example would be a man between 30 and 60 years of age who is an agricultural worker in an endemic region and who presents with any of the following findings:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chronic lung infiltrates (fibrosis, alveolar <span class=\"nowrap\">and/or</span> interstitial infiltrates, cavities) with or without symptoms (cough, dyspnea)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chronic mucosal ulcers in the upper airways</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Sialorrhea, odynophagia, hoarseness</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chronic skin lesions (nodules, ulcers) around natural orifices or on the lower limbs</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Asymmetric lymph node enlargement (especially in the cervical region) with or without fistula formation. (See <a href=\"#H2\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H17\"><span class=\"h2\">Approach to diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The initial evaluation of patients with suspected chronic paracoccidioidomycosis should include all of the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Imaging of affected areas (eg, chest radiograph and computed tomography [CT]). Since most patients have chronic pulmonary involvement, multiple lesions, and fibrosis, CT scanning is required to optimally characterize the lung lesions. A baseline chest radiograph is also useful since this modality can be used to follow response to therapy.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Direct examination and culture of sputum <span class=\"nowrap\">and/or</span> biopsy specimens, depending upon sites of involvement</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Serologic testing (preferably by quantitative immunodiffusion)</p><p/><p>Although the diagnosis is often established by direct examination and culture, serologic testing is important in order to have a baseline result for comparison during therapy since a reduction in antibody titers is expected during treatment (see <a href=\"topic.htm?path=treatment-of-paracoccidioidomycosis#H22\" class=\"medical medical_review\">&quot;Treatment of paracoccidioidomycosis&quot;, section on 'Serologic testing'</a>). A positive serologic test is also useful in cases in which direct microscopy and culture do not yield a positive result.</p><p>During the initial evaluation of patients with chronic paracoccidioidomycosis, special attention should be devoted to the lungs (radiographic studies, pulmonary function tests), larynx, oral cavity, adrenal glands, and central nervous system. Abdominal and central nervous system CT scans should be requested only for patients with signs and symptoms suggestive of specific organ involvement.</p><p>Considering the high frequency of adrenal dysfunction in patients with paracoccidioidomycosis, all patients (regardless of symptoms) should undergo adrenal evaluation at presentation. This includes an early morning serum cortisol level and evaluation of cortisol production in response to exogenous ACTH administration. Patients with clinical suspicion of Addison's disease require a complete investigation of adrenal function. (See <a href=\"topic.htm?path=diagnosis-of-adrenal-insufficiency-in-adults\" class=\"medical medical_review\">&quot;Diagnosis of adrenal insufficiency in adults&quot;</a> and <a href=\"topic.htm?path=evaluation-of-the-response-to-acth-in-adrenal-insufficiency\" class=\"medical medical_review\">&quot;Evaluation of the response to ACTH in adrenal insufficiency&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h3\">Disseminated</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of chronic paracoccidioidomycosis causing disseminated disease is usually made by the detection of characteristic budding yeasts in a tissue biopsy or scrapings of skin or mucosal lesions. Direct examination and cultures of sputum are also useful in detecting fungal elements suggestive of <em>P. brasiliensis</em>. In these patients, the sensitivity of serology is very high and antibody titers by immunodiffusion usually range between 1:8 and 1:64. (See <a href=\"#H10\" class=\"local\">'Diagnosis'</a> above.)</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h3\">Unifocal</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis may be challenging in situations in which the disease is restricted to a single organ, especially if the infection is in the central nervous system. In such cases, sensitivity of serology is low, tissue is difficult to obtain, and cultures are frequently negative. The detection of specific antigens (gp48 and gp70) either in the blood or cerebrospinal fluid using an immunoenzymatic assay may be helpful [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/32\" class=\"abstract_t\">32</a>]. (See <a href=\"#H15\" class=\"local\">'Experimental methods'</a> above.)</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h1\">IMMUNOCOMPROMISED HOSTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Paracoccidioidomycosis has been reported infrequently among patients with HIV [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/38-40\" class=\"abstract_t\">38-40</a>] or other causes of T cell&ndash;mediated immunodeficiency, such as cancer [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/41\" class=\"abstract_t\">41</a>] and solid organ transplantation [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/42,43\" class=\"abstract_t\">42,43</a>].</p><p>HIV-infected individuals with paracoccidioidomycosis usually have disseminated disease characterized by more exuberant and widespread findings than those observed in immunocompetent patients with the chronic form [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/2,38,40\" class=\"abstract_t\">2,38,40</a>]. In a retrospective study that included 53 patients with HIV and 106 patients without HIV, HIV-infected patients had more rapid progression of disease and were significantly more likely to have fever (96 versus 51 percent), lymphadenopathy (80 versus 62 percent), hepatomegaly (64 versus 20 percent), and skin lesions (67 versus 46 percent) but were less likely to have ulceration of the oral or nasal mucosa (21 versus 51 percent) compared with non&ndash;HIV-infected patients [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/40\" class=\"abstract_t\">40</a>].</p><p>Eighty-five percent of HIV-infected individuals had pulmonary involvement compared with 69 percent of non&ndash;HIV-infected individuals, a difference which did not reach statistical significance. HIV-infected patients were significantly less likely to have a positive serologic test (76 versus 96 percent). HIV-infected individuals were significantly more likely to have suffered relapse by 24 months (19 versus 3 percent). The majority of HIV-infected patients (84 percent) had a CD4 cell count &le;200 <span class=\"nowrap\">cells/microL</span>.</p><p>This study suggests that paracoccidioidomycosis in HIV-infected patients has different clinical characteristics than the chronic form typically seen in immunocompetent adults. It is surprising that paracoccidioidomycosis does not occur more frequently in HIV-infected patients who live in endemic regions; in such patients, histoplasmosis and cryptococcosis occur more commonly than paracoccidioidomycosis despite a higher incidence of the latter disease in immunocompetent individuals [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/40\" class=\"abstract_t\">40</a>].</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Paracoccidioidomycosis is a systemic endemic mycotic disease caused by the thermally dimorphic fungi of the genus <em>Paracoccidioides</em>, with two species: <em>Paracoccidioides brasiliensis </em>and <em>Paracoccidioides lutzii</em>. The disease has a geographic distribution limited to Central and South America. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Paracoccidioides </em>spp typically causes asymptomatic pulmonary infection. However, if the infection is not contained by the host, the disease may evolve into one of two patterns: the chronic form, which represents reactivation of the primary infection, and the <span class=\"nowrap\">acute/subacute</span> form. (See <a href=\"#H2\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Over 90 percent of cases of paracoccidioidomycosis occur as the chronic form, which most commonly affects men who work in agriculture. (See <a href=\"#H2\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The lungs and oral mucosa are the most frequently involved sites in chronic paracoccidioidomycosis. (See <a href=\"#H3\" class=\"local\">'Signs and symptoms'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An important aspect of chronic paracoccidioidomycosis is the development of sequelae, mostly represented by chronic respiratory failure, which results from fibrosis. Lung scarring occurs even in the setting of adequate antifungal therapy. Adrenal dysfunction is also frequently reported and mostly represented by asymptomatic limited reserve of adrenal function. (See <a href=\"#H8\" class=\"local\">'Sequelae'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with chronic paracoccidioidomycosis with lung involvement, there is a broad differential diagnosis, which includes infectious causes such as tuberculosis, fungal infections (especially histoplasmosis), and noninfectious causes such as carcinoma, sarcoidosis, and idiopathic pulmonary fibrosis. (See <a href=\"#H9\" class=\"local\">'Differential diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of paracoccidioidomycosis is based upon the microscopic visualization of fungal elements suggestive of <em>Paracoccidioides </em>spp <span class=\"nowrap\">and/or</span> by culturing this fungus from clinical specimens. Serologic testing (preferably quantitative immunodiffusion) can be useful for both diagnosis and monitoring the response to therapy. (See <a href=\"#H10\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chronic paracoccidioidomycosis should be suspected in patients with chronic lung infiltrates (fibrosis, alveolar <span class=\"nowrap\">and/or</span> interstitial infiltrates, cavities) with or without symptoms (cough, dyspnea); chronic mucosal ulcers in the upper airways; sialorrhea, odynophagia, or hoarseness; chronic skin lesions (nodules, ulcers); <span class=\"nowrap\">and/or</span> asymmetric lymph node enlargement (especially in the cervical region). (See <a href=\"#H16\" class=\"local\">'Evaluation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The initial evaluation of patients with suspected paracoccidioidomycosis should include imaging of affected areas (eg, chest computed tomography scan), direct examination and culture of sputum <span class=\"nowrap\">and/or</span> biopsy specimens, and serologic testing. (See <a href=\"#H17\" class=\"local\">'Approach to diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Paracoccidioidomycosis has been reported infrequently among patients with HIV or other causes of T cell&ndash;mediated immunodeficiency, such as cancer and solid organ transplantation. (See <a href=\"#H20\" class=\"local\">'Immunocompromised hosts'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>HIV-infected individuals with paracoccidioidomycosis usually have disseminated disease characterized by more exuberant and widespread findings than those observed in immunocompetent patients with the chronic form. (See <a href=\"#H20\" class=\"local\">'Immunocompromised hosts'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/1\" class=\"nounderline abstract_t\">Travassos LR, Taborda CP, Colombo AL. Treatment options for paracoccidioidomycosis and new strategies investigated. Expert Rev Anti Infect Ther 2008; 6:251.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/2\" class=\"nounderline abstract_t\">Brummer E, Castaneda E, Restrepo A. Paracoccidioidomycosis: an update. Clin Microbiol Rev 1993; 6:89.</a></li><li class=\"breakAll\">Restrepo A, Tobon AM, Agudelo CA. Paracoccidioidomycosis. In: Diagnosis and Treatment of Human Mycoses, 1st edition, Hospenthal, DR, Rinaldi, MG (Eds), Humana Press, Totowa, NJ 2008. p.331.</li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/4\" class=\"nounderline abstract_t\">Restrepo A, Benard G, de Castro CC, et al. Pulmonary paracoccidioidomycosis. Semin Respir Crit Care Med 2008; 29:182.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/5\" class=\"nounderline abstract_t\">Coutinho ZF, Wanke B, Travassos C, et al. Hospital morbidity due to paracoccidioidomycosis in Brazil (1998-2006). Trop Med Int Health 2015; 20:673.</a></li><li class=\"breakAll\">Restrepo A, Tobon AM. Paracoccidioides brasiliensis. In: Principles and Practice of Infectious Diseases, 6th ed, Mandell GL, Bennett JE, Dolin R (Eds), Elsevier, Philadelphia 2005. p.3062.</li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/7\" class=\"nounderline abstract_t\">Correa AL, Franco L, Restrepo A . Paracoccidioidomicosis: Coexistencia de lesiones pulmonares y patologia pulmonar silente. Acta Med Colomb 1991; 16:304.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/8\" class=\"nounderline abstract_t\">Tob&oacute;n AM, Agudelo CA, Osorio ML, et al. Residual pulmonary abnormalities in adult patients with chronic paracoccidioidomycosis: prolonged follow-up after itraconazole therapy. Clin Infect Dis 2003; 37:898.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/9\" class=\"nounderline abstract_t\">Bicalho RN, Santo MF, de Aguiar MC, Santos VR. Oral paracoccidioidomycosis: a retrospective study of 62 Brazilian patients. Oral Dis 2001; 7:56.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/10\" class=\"nounderline abstract_t\">Silva CO, Almeida AS, Pereira AA, et al. Gingival involvement in oral paracoccidioidomycosis. J Periodontol 2007; 78:1229.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/11\" class=\"nounderline abstract_t\">Godoy H, Reichart PA. Oral manifestations of paracoccidioidomycosis. Report of 21 cases from Argentina. Mycoses 2003; 46:412.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/12\" class=\"nounderline abstract_t\">Sant'Anna GD, Mauri M, Arrarte JL, Camargo H Jr. Laryngeal manifestations of paracoccidioidomycosis (South American blastomycosis). Arch Otolaryngol Head Neck Surg 1999; 125:1375.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/13\" class=\"nounderline abstract_t\">Ramos-E-Silva M, Saraiva Ldo E. Paracoccidioidomycosis. Dermatol Clin 2008; 26:257.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/14\" class=\"nounderline abstract_t\">Yamaga LY, Benard G, Hironaka FH, et al. The role of gallium-67 scan in defining the extent of disease in an endemic deep mycosis, paracoccidioidomycosis: a predominantly multifocal disease. Eur J Nucl Med Mol Imaging 2003; 30:888.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/15\" class=\"nounderline abstract_t\">Colombo AL, Fai&ccedil;al S, Kater CE. Systematic evaluation of the adrenocortical function in patients with paracoccidioidomycosis. Mycopathologia 1994; 127:89.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/16\" class=\"nounderline abstract_t\">Paniago AM, de Oliveira PA, Aguiar ES, et al. Neuroparacoccidioidomycosis: analysis of 13 cases observed in an endemic area in Brazil. Trans R Soc Trop Med Hyg 2007; 101:414.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/17\" class=\"nounderline abstract_t\">O&ntilde;ate JM, Tob&oacute;n AM, Restrepo A. [Adrenal gland insufficiency secondary to paracoccidioidomycosis]. Biomedica 2002; 22:280.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/18\" class=\"nounderline abstract_t\">Amstalden EM, Xavier R, Kattapuram SV, et al. Paracoccidioidomycosis of bones and joints. A clinical, radiologic, and pathologic study of 9 cases. Medicine (Baltimore) 1996; 75:213.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/19\" class=\"nounderline abstract_t\">Doria AS, Taylor GA. Bony involvement in paracoccidioidomycosis. Pediatr Radiol 1997; 27:67.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/20\" class=\"nounderline abstract_t\">Severo LC, Kauer CL, Oliveira Fd, et al. Paracoccidioidomycosis of the male genital tract. Report of eleven cases and a review of Brazilian literature. Rev Inst Med Trop Sao Paulo 2000; 42:38.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/21\" class=\"nounderline abstract_t\">Cruz AA, Zenha F, Silva JT Jr, Martinez R. Eyelid involvement in paracoccidioidomycosis. Ophthal Plast Reconstr Surg 2004; 20:212.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/22\" class=\"nounderline abstract_t\">Dantas AM, Yamane R, Camara AG. South American blastomycosis: ophthalmic and oculomotor nerve lesions. Am J Trop Med Hyg 1990; 43:386.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/23\" class=\"nounderline abstract_t\">do Valle AC, Guimar&atilde;es RR, Lopes DJ, Capone D. [Thoracic radiologic aspects in paracoccidioidomycosis]. Rev Inst Med Trop Sao Paulo 1992; 34:107.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/24\" class=\"nounderline abstract_t\">Barreto MM, Marchiori E, Amorim VB, et al. Thoracic paracoccidioidomycosis: radiographic and CT findings. Radiographics 2012; 32:71.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/25\" class=\"nounderline abstract_t\">Costa AN, Benard G, Albuquerque AL, et al. The lung in paracoccidioidomycosis: new insights into old problems. Clinics (Sao Paulo) 2013; 68:441.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/26\" class=\"nounderline abstract_t\">Blotta MH, Mamoni RL, Oliveira SJ, et al. Endemic regions of paracoccidioidomycosis in Brazil: a clinical and epidemiologic study of 584 cases in the southeast region. Am J Trop Med Hyg 1999; 61:390.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/27\" class=\"nounderline abstract_t\">de Camargo ZP. Serology of paracoccidioidomycosis. Mycopathologia 2008; 165:289.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/28\" class=\"nounderline abstract_t\">De Camargo Z, Unterkircher C, Campoy SP, Travassos LR. Production of Paracoccidioides brasiliensis exoantigens for immunodiffusion tests. J Clin Microbiol 1988; 26:2147.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/29\" class=\"nounderline abstract_t\">Moreto TC, Marques ME, de Oliveira ML, et al. Accuracy of routine diagnostic tests used in paracoccidioidomycosis patients at a university hospital. Trans R Soc Trop Med Hyg 2011; 105:473.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/30\" class=\"nounderline abstract_t\">Batista J Jr, de Camargo ZP, Fernandes GF, et al. Is the geographical origin of a Paracoccidioides brasiliensis isolate important for antigen production for regional diagnosis of paracoccidioidomycosis? Mycoses 2010; 53:176.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/31\" class=\"nounderline abstract_t\">Gegembauer G, Araujo LM, Pereira EF, et al. Serology of paracoccidioidomycosis due to Paracoccidioides lutzii. PLoS Negl Trop Dis 2014; 8:e2986.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/32\" class=\"nounderline abstract_t\">Marques da Silva SH, Colombo AL, Blotta MH, et al. Detection of circulating gp43 antigen in serum, cerebrospinal fluid, and bronchoalveolar lavage fluid of patients with paracoccidioidomycosis. J Clin Microbiol 2003; 41:3675.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/33\" class=\"nounderline abstract_t\">Marques da Silva SH, Queiroz-Telles F, Colombo AL, et al. Monitoring gp43 antigenemia in Paracoccidioidomycosis patients during therapy. J Clin Microbiol 2004; 42:2419.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/34\" class=\"nounderline abstract_t\">Dos Santos PO, Rodrigues AM, Fernandes GF, et al. Immunodiagnosis of paracoccidioidomycosis due to Paracoccidioides brasiliensis using a latex test: detection of specific antibody anti-gp43 and specific antigen gp43. PLoS Negl Trop Dis 2015; 9:e0003516.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/35\" class=\"nounderline abstract_t\">Motoyama AB, Venancio EJ, Brand&atilde;o GO, et al. Molecular identification of Paracoccidioides brasiliensis by PCR amplification of ribosomal DNA. J Clin Microbiol 2000; 38:3106.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/36\" class=\"nounderline abstract_t\">Gomes GM, Cisalpino PS, Taborda CP, de Camargo ZP. PCR for diagnosis of paracoccidioidomycosis. J Clin Microbiol 2000; 38:3478.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/37\" class=\"nounderline abstract_t\">Nobrega de Almeida J Jr, Del Negro GM, Grenfell RC, et al. Matrix-assisted laser desorption ionization-time of flight mass spectrometry for differentiation of the dimorphic fungal species Paracoccidioides brasiliensis and Paracoccidioides lutzii. J Clin Microbiol 2015; 53:1383.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/38\" class=\"nounderline abstract_t\">Silva-Vergara ML, Teixeira AC, Curi VG, et al. Paracoccidioidomycosis associated with human immunodeficiency virus infection. Report of 10 cases. Med Mycol 2003; 41:259.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/39\" class=\"nounderline abstract_t\">Paniago AM, de Freitas AC, Aguiar ES, et al. Paracoccidioidomycosis in patients with human immunodeficiency virus: review of 12 cases observed in an endemic region in Brazil. J Infect 2005; 51:248.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/40\" class=\"nounderline abstract_t\">Morej&oacute;n KM, Machado AA, Martinez R. Paracoccidioidomycosis in patients infected with and not infected with human immunodeficiency virus: a case-control study. Am J Trop Med Hyg 2009; 80:359.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/41\" class=\"nounderline abstract_t\">Shikanai-Yasuda MA, Concei&ccedil;&atilde;o YM, Kono A, et al. Neoplasia and paracoccidioidomycosis. Mycopathologia 2008; 165:303.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/42\" class=\"nounderline abstract_t\">Zavascki AP, Bienardt JC, Severo LC. Paracoccidioidomycosis in organ transplant recipient: case report. Rev Inst Med Trop Sao Paulo 2004; 46:279.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronic-paracoccidioidomycosis/abstract/43\" class=\"nounderline abstract_t\">Shikanai-Yasuda MA, Duarte MI, Nunes DF, et al. Paracoccidioidomycosis in a renal transplant recipient. J Med Vet Mycol 1995; 33:411.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 2435 Version 12.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H21\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Signs and symptoms</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">- Lungs</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">- Mucosa</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">- Other sites</a></li></ul></li><li><a href=\"#H7\" id=\"outline-link-H7\">Radiographic findings</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Sequelae</a></li></ul></li><li><a href=\"#H9\" id=\"outline-link-H9\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">DIAGNOSIS</a><ul><li><a href=\"#H11\" id=\"outline-link-H11\">Microscopy</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Culture</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">Pathology</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">Serologic tests</a></li><li><a href=\"#H3302332640\" id=\"outline-link-H3302332640\">Skin testing</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">Experimental methods</a></li></ul></li><li><a href=\"#H16\" id=\"outline-link-H16\">EVALUATION</a><ul><li><a href=\"#H17\" id=\"outline-link-H17\">Approach to diagnosis</a><ul><li><a href=\"#H18\" id=\"outline-link-H18\">- Disseminated</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">- Unifocal</a></li></ul></li></ul></li><li><a href=\"#H20\" id=\"outline-link-H20\">IMMUNOCOMPROMISED HOSTS</a></li><li><a href=\"#H21\" id=\"outline-link-H21\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/2435|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=ID/63969\" class=\"graphic graphic_diagnosticimage\">- Paracocci imaging</a></li><li><a href=\"image.htm?imageKey=ID/74974\" class=\"graphic graphic_diagnosticimage\">- Severe pulmonary paracocci</a></li></ul></li><li><div id=\"ID/2435|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/69875\" class=\"graphic graphic_picture\">- Oral paracocci</a></li><li><a href=\"image.htm?imageKey=ID/62412\" class=\"graphic graphic_picture\">- Chronic paracocci</a></li><li><a href=\"image.htm?imageKey=ID/57011\" class=\"graphic graphic_picture\">- Paracocci sequelae</a></li><li><a href=\"image.htm?imageKey=ID/74383\" class=\"graphic graphic_picture\">- Microscopy pilot wheel</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-acute-subacute-paracoccidioidomycosis\" class=\"medical medical_review\">Clinical manifestations and diagnosis of acute/subacute paracoccidioidomycosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-and-treatment-of-pulmonary-histoplasmosis\" class=\"medical medical_review\">Diagnosis and treatment of pulmonary histoplasmosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-adrenal-insufficiency-in-adults\" class=\"medical medical_review\">Diagnosis of adrenal insufficiency in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-of-the-response-to-acth-in-adrenal-insufficiency\" class=\"medical medical_review\">Evaluation of the response to ACTH in adrenal insufficiency</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mycology-and-epidemiology-of-paracoccidioidomycosis\" class=\"medical medical_review\">Mycology and epidemiology of paracoccidioidomycosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-paracoccidioidomycosis\" class=\"medical medical_review\">Treatment of paracoccidioidomycosis</a></li></ul></div></div>","javascript":null}